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Introduction
Because most children with oligoarticular juvenile idio-
pathic arthritis (o-JIA) were mildly affected (Steinblocker
functional class I, c.a.85%), o-JIA is tend to be thought of
as a mild subtype of JIA. However, 6% of them were
unable to participate in a full school program 5 years after
diagnosis, and 0.5% of children with o-JIA progressed to
class III or IV, severe to terminal stages. Moreover, in 20%
of o-JIA patients there is a progressive increase in the
number of affected joints after the first 6 months of
disease (extended type). These severe patients had never
gone into remission despite the conventional therapy.
Objectives
To assess the efficacy and adverse events of tocilizumab
for children with o-JIA refractory to the methotrexate
(MTX) and prednisone (PSL) therapy.
Methods
Eight patients with o-JIA refractory to MTX and PSL
therapy were eligible in this study, including 7 patients
with a persistent type and 1 patient with an extended
type. Synovial inflammation and joint effusion were
demonstrated by ultrasound and power Doppler exami-
nation as well as physical examination and other labora-
tory findings. Patients complicated with uveitis were
excluded from the study because their arthritis had
responded well to the conventional therapy. All patients
were female, and the median age at analysis was
10.1 years. Both the rheumatoid factor and the anti-CCP
antibody were positive in the same 4 patients. Tocilizu-
mab (8 mg/kg) was infused every 4 weeks. Efficacy and
tolerability were assessed by VAS28-CRP, matrix metallo-
proteinase (MMP)-3 levels, and PSL doses.
Results
The affected joints were both knee joints (2/8), one knee
joint (2/8), right knee joint and both foot joints (1/8),
and both wrist joints (2/8). One patient with the
extended type had arthritis primarily on knee and foot
joints that extended to elbow and wrists joints within
6 months. The number of tender and swollen joints
were decreased to none in 5 out of 8 patients within
6 months. Only one patient needed 12 months to
become arthritis-free after TCZ initiation. The serum
levels of MMP-3 in all patients were within baseline
levels during the 6 months with TCZ treatment, though
in 5 of them, MMP-3 levels were in the normal range
at the beginning of TCZ administration. The mean
doses of PSL were 7.5 mg/day before TCZ. They
decreased to 3.1 mg/day after 6 months with TCZ, and
then to none after 12 months. No serious adverse events
were observed.
Conclusion
TCZ was effective and well tolerated for patients with o-
JIA refractory to conventional treatments.
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